De novo hepatitis B infection following liver transplantation with core antibody positive grafts: The role of surface antibody status in guiding long‐term prophylaxis
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15263 ↗At a glance
Journal article in Clinical Transplantation, 2024. Written by Brad Busebee and 5 co-authors. Institution: Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: Liver Transplantation, Hepatitis B. Cited 5 times so far (Crossref); 19 references.
Abstract (original language)
Liver transplantation (LT) with hepatitis B core antibody (anti‐HBc) positive grafts to hepatitis B surface‐antigen (HBsAg) negative recipients is safe and has likely contributed to improvements in organ access over the years. The incidence of de novo hepatitis B infection (HBV) in these instances is low with appropriate prophylaxis and is affected by recipient immunologic status. There is debate as to whether hepatitis B surface antibody (anti‐HBs) positivity may safely inform prophylaxis discontinuation post‐LT. In this retrospective study of all hepatitis B surface antigen (HBsAg) negative recipients of anti‐HBc positive organs at three large academic centers between January 2014 and December 2019, nine LT recipients discontinued prophylaxis after developing anti‐HBs antibodies 1 year or later post‐LT. Three of the nine patients (33%) developed de novo HBV, defined by positive HBsAg or hepatitis B virus (HBV) DNA, during the study period. The remaining six patients had no evidence of HBV infection after a mean follow‐up of 37 months. The patients without de novo HBV had higher anti‐HBs titers at the time of prophylaxis discontinuation and were less likely to have negative anti‐HBs at the time of transplant or negative anti‐HBc at any time point. These results suggest that quantitative anti‐HBs titer thresholds rather than qualitative anti‐HBs positivity at 1 year or later after LT should be used to identify patients at decreased risk of de novo infection and help guide prophylaxis duration.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Research, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Internal Medicine, Division of Gastroenterology, Mayo Clinic, Scottsdale, Arizona, USA.
- Department of Surgery, Division of Transplant Surgery, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Internal Medicine, Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID profiles: Brad Busebee, Timucin Taner
Cite
APA
Busebee, B., Myhre, L., Mara, K., Aqel, B., Taner, T., & Watt, K. D. (2024). De novo hepatitis B infection following liver transplantation with core antibody positive grafts: The role of surface antibody status in guiding long‐term prophylaxis. Clinical Transplantation. https://doi.org/10.1111/ctr.15263
Vancouver
Busebee B, Myhre L, Mara K, Aqel B, Taner T, Watt KD. De novo hepatitis B infection following liver transplantation with core antibody positive grafts: The role of surface antibody status in guiding long‐term prophylaxis. Clinical Transplantation. 2024. doi:10.1111/ctr.15263
BibTeX
@article{Busebee2024,
author = {Busebee, Brad and Myhre, Laura and Mara, Kristin and Aqel, Bashar and Taner, Timucin and Watt, Kymberly D},
title = {De novo hepatitis B infection following liver transplantation with core antibody positive grafts: The role of surface antibody status in guiding long‐term prophylaxis},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15263}
}
EUVIMED